ES2103468T3 - Tratamiento de la inflamacion intestinal. - Google Patents

Tratamiento de la inflamacion intestinal.

Info

Publication number
ES2103468T3
ES2103468T3 ES93904830T ES93904830T ES2103468T3 ES 2103468 T3 ES2103468 T3 ES 2103468T3 ES 93904830 T ES93904830 T ES 93904830T ES 93904830 T ES93904830 T ES 93904830T ES 2103468 T3 ES2103468 T3 ES 2103468T3
Authority
ES
Spain
Prior art keywords
treatment
intestinal inflammation
tissus
ibd
endothelium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93904830T
Other languages
English (en)
Inventor
Roy R Lobb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25268692&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2103468(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Inc filed Critical Biogen Inc
Application granted granted Critical
Publication of ES2103468T3 publication Critical patent/ES2103468T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70542—CD106
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

SE DESCRIBE UN METODO PARA EL TRATAMIENTO DE (IBD) (INFLAMMATORY BOWEL DISEASE O). EL METODO COMPRENDE LA ADMINISTRACION DE UN ANTICUERPO, POLIPEPTIDO U OTRA MOLECULA COMPRENDIENDO VLA-4, UNA MOLECULA SUPERFICIAL EXPRESADA EN LA MAYOR CLASE DE TIPOS DE GLOBULOS SANGUINEOS BLANCOS E IMPLICADA EN LA ADHERENCIA DE LEUCOCITOS AL ENDOTELIO Y OTROS TEJIDOS EN EL TUBO DIGESTIVO.
ES93904830T 1992-02-12 1993-02-02 Tratamiento de la inflamacion intestinal. Expired - Lifetime ES2103468T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83513992A 1992-02-12 1992-02-12

Publications (1)

Publication Number Publication Date
ES2103468T3 true ES2103468T3 (es) 1997-09-16

Family

ID=25268692

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93904830T Expired - Lifetime ES2103468T3 (es) 1992-02-12 1993-02-02 Tratamiento de la inflamacion intestinal.

Country Status (10)

Country Link
EP (1) EP0625912B1 (es)
JP (3) JPH07506566A (es)
AT (1) ATE151642T1 (es)
AU (1) AU674302B2 (es)
CA (1) CA2129637C (es)
DE (1) DE69309906T2 (es)
DK (1) DK0625912T3 (es)
ES (1) ES2103468T3 (es)
GR (1) GR3024041T3 (es)
WO (1) WO1993015764A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
AU689454B2 (en) 1992-11-13 1998-04-02 Board Of Regents Of The University Of Washington, The Peripheralization of hematopoietic stem cells
AU727187B2 (en) * 1993-02-09 2000-12-07 Biogen Idec Ma Inc. Treatment for insulin dependent diabetes
ES2114183T5 (es) * 1993-02-09 2006-06-16 Biogen Idec Ma, Inc. Anticuerpo para el tratamiento de la diabetes dependiente de la insulina.
ZA947006B (en) * 1993-09-15 1995-05-02 Univ Emory Method of inhibiting binding of reticulocytes to endothelium by interfering with vla-4/vcam-1 interactions
AU703152B2 (en) * 1994-01-25 1999-03-18 Biogen Ma Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
KR100628818B1 (ko) 1998-09-14 2006-09-27 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 인테그린 길항제를 사용하여 다발성 골수종 및 골수종에의한 골흡수를 치료하는 방법
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
AU2003211560A1 (en) 2002-02-20 2003-09-09 Ajinomoto Co., Inc. Novel phenylalanine derivative
AR038605A1 (es) 2002-02-25 2005-01-19 Elan Pharm Inc Uso de agentes para la manufactura de un medicamento para el tratamiento de inflamacion y composiciones para dicho tratamiento
KR20110098980A (ko) 2003-12-22 2011-09-02 아지노모토 가부시키가이샤 신규한 페닐알라닌 유도체
US20100150915A1 (en) 2007-02-20 2010-06-17 Stewart Edward J Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
JP4652356B2 (ja) 2007-02-26 2011-03-16 アルプス電気株式会社 ターンシグナルスイッチ装置
EA022201B1 (ru) 2008-04-11 2015-11-30 Мерримак Фармасьютикалз, Инк. Агент, способный связываться с опухолевой клеткой, содержащий линкер на основе hsa, и его применение
HUE050858T2 (hu) 2010-04-16 2021-01-28 Biogen Ma Inc VLA-4 ellenes antitestek
US10040855B2 (en) 2011-05-02 2018-08-07 Millennium Pharmaceuticals, Inc. Formulation for anti-α4β7 antibody
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
CN109884295B (zh) * 2017-12-25 2022-03-08 苏州和锐生物科技有限公司 假单胞菌多肽、抗体捕获器件及试剂盒
KR102848349B1 (ko) 2018-06-04 2025-08-21 바이오젠 엠에이 인코포레이티드 감소된 효과기 기능을 갖는 항-ｖｌａ-4 항체

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE114972T1 (de) * 1987-11-02 1994-12-15 Baylor College Medicine Verwendung von icam-1 oder ihre funktionelle derivate zur behandlung unspezifischer entzündungen.
US5147637A (en) * 1988-06-07 1992-09-15 The Rockefeller University Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma
DK162890D0 (da) 1990-07-06 1990-07-06 Novo Nordisk As Polypeptid
JPH07502727A (ja) * 1991-10-01 1995-03-23 ザ・ジエネラル・ホスピタル・コーポレーシヨン 接着分子に対する抗体を用いた同種移植片拒絶の防止

Also Published As

Publication number Publication date
HK1007683A1 (en) 1999-04-23
WO1993015764A1 (en) 1993-08-19
ATE151642T1 (de) 1997-05-15
CA2129637A1 (en) 1993-08-19
EP0625912A1 (en) 1994-11-30
EP0625912B1 (en) 1997-04-16
JP4108572B2 (ja) 2008-06-25
DK0625912T3 (da) 1997-10-27
JP2004002472A (ja) 2004-01-08
CA2129637C (en) 1999-05-04
DE69309906T2 (de) 1997-11-06
AU3605993A (en) 1993-09-03
JP2007045843A (ja) 2007-02-22
AU674302B2 (en) 1996-12-19
GR3024041T3 (en) 1997-10-31
DE69309906D1 (de) 1997-05-22
JPH07506566A (ja) 1995-07-20

Similar Documents

Publication Publication Date Title
ES2103468T3 (es) Tratamiento de la inflamacion intestinal.
ATE332159T1 (de) System zum sammeln von blut ohne es zu beschädigen
DE69309044D1 (de) Behandlung von asthma
DK1014996T3 (da) Præparater indeholdende saccharid til behandling af Alzheimers sygdom og andre amyloidoser
FR2633940B3 (fr) Scleroglucane traite au glyoxal et son procede d'obtention
ES2094733T3 (es) Deteccion de enfermedades o disfunciones neurologicas.
AU1049788A (en) Methods and peptides for the treatment of non-ige-mediated diseases
CA2034881A1 (en) Factor x-laci hybrid protein
EP0937982A3 (de) Diagnostikum und Therapeutikum zur Behandlung der autoimmunen Hepatitis
FI953565A7 (fi) Uusi antikoagulanttikofaktoriaktiivisuus
ATE76877T1 (de) Hapten-protein-konjugate und ihre verwendung.
WO1998051780A3 (en) Method for increasing yields or recombinant proteins
SE8904007D0 (sv) Monoklona antikroppar och diagnostiseringsmetod
ES2049021T3 (es) Metodo de recuperar la proteina epi purificada a partir de una solucion, especialmente una solucion de fermentacion.
EP0728216A4 (en) DETECTION OF ALZHEIMER'S DISEASE AND OTHER DISEASES BY MEANS OF AN IMPROVED METHOD OF PHOTO AFFINITY MARKING
RU96109171A (ru) Способ идентификации тела погибшего
ES2056872T3 (es) Proteina pp4-x anticoagulante, su preparacion y empleo.
RU93004826A (ru) Способ мездрения кож и шкур
FR2643118B1 (fr) Pompe d'aspiration
FR2640634B1 (fr) Gelatine fluoree et procede d'obtention
FR2737209B1 (fr) Peptide capable d'etre reconnu par des anticorps reconnaissant l'antigene c33 du virus de l'hepatite c
EP0749981A4 (en) MONOCLONAL ANTIBODY
RU95106901A (ru) Способ моделирования антиперистальтики кишечника в эксперименте
FR2621926B1 (fr) Procede de traitement d'un mout de fermentation renfermant un polysaccharide dans le but d'en accroitre la filtrabilite et utilisation de ce mout en recuperation assistee du petrole
SU1018624A1 (ru) Способ наложени анастомоза между интра и экстраперитонеально расположенными органами

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 625912

Country of ref document: ES